Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -6 of 6
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
1.
A Study of OGX-011/Gemcitabine/Platinum-Based Regimen in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Closed
18 and over
Pharmaceutical / Industry
OGX-011-05
NCT00138658
2.
A Study to Evaluate the Safety and Feasibility of Using OGX-011 in Combination With Second Line Chemotherapy in Patients With Hormone Refractory Prostate Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Closed
18 and over
Pharmaceutical / Industry
OGX011-07
NCT00327340
Last Modified:
2/8/2007
 
First Published:
11/18/2005
3.
Phase II Randomized Study of Docetaxel and Prednisone With or Without OGX-011 in Patients With Hormone-Refractory Locally Recurrent or Metastatic Prostate Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
18 and over
Other
CAN-NCIC-IND165
ONCOGENEX-OGX-011-03, NCT00258388, FHCRC-6084, UWCC-UW-6084, UWCC-06-0499-H/D, IND165
Last Modified:
3/19/2007
 
First Published:
11/18/2005
4.
Phase II Study of OGX-011 and Docetaxel in Women With Locally Advanced or Metastatic Breast Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
18 and over
Other
CAN-NCIC-IND164
ONCOGENEX-OGX-011-06, NCT00258375, IND164
Last Modified:
9/13/2005
 
First Published:
1/26/2003
5.
Phase I Study of Neoadjuvant Hormonal Therapy and OGX-011 (Clusterin Antisense Oligonucleotide) Before Radical Prostatectomy in Patients With Adenocarcinoma of the Prostate
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Completed
Over 18
Other, Pharmaceutical / Industry
CAN-NCIC-IND153
ONCOGENEX-OGX-01-01, NCT00054106, IND153
Last Modified:
3/21/2008
 
First Published:
5/4/2007
6.
Phase I Study of OGX-011 and Docetaxel in Patients With Metastatic or Locally Recurrent Solid Tumors
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Biomarker/Laboratory analysis, Treatment
Completed
18 and over
Other
CAN-NCIC-IND154
IND154, ONCOGENEX-OGX-01-02, NCT00471432
Select All on One Page
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute